These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33861693)

  • 21. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biogen's early Alzheimer's data raise hopes, some eyebrows.
    Ratner M
    Nat Biotechnol; 2015 May; 33(5):438. PubMed ID: 25965736
    [No Abstract]   [Full Text] [Related]  

  • 23. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 24. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
    Yuksel JM; Noviasky J; Britton S
    Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
    [No Abstract]   [Full Text] [Related]  

  • 25. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 27. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease.
    Schneider LS
    Alzheimers Dement; 2014 Mar; 10(2):247-50. PubMed ID: 24698029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.
    Heidebrink JL; Paulson HL
    Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 30. Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
    Høilund-Carlsen PF; Werner TJ; Alavi A; Revheim ME
    Clin Nucl Med; 2022 Jul; 47(7):625-626. PubMed ID: 35452007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance.
    Rose RV; Kass JS
    Continuum (Minneap Minn); 2022 Jun; 28(3):937-941. PubMed ID: 35678410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 34. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 36. Preparing the health-care system to pay for new Alzheimer's drugs.
    Lin PJ; Cohen JT; Neumann PJ
    Alzheimers Dement; 2020 Nov; 16(11):1568-1570. PubMed ID: 32808733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 38. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 39. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials.
    Ritchie M; Witbracht M; Nuño MM; Hoang D; Gillen DL; Grill JD
    J Alzheimers Dis; 2022; 90(3):1291-1300. PubMed ID: 36245381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.